Scott Thomas - Seer Chief Officer
| SEER Stock | USD 2.48 0.10 4.20% |
Insider
Scott Thomas is Chief Officer of Seer Inc
| Age | 51 |
| Address | 3800 Bridge Parkway, Redwood City, CA, United States, 94065 |
| Phone | 650 453 0000 |
| Web | https://seer.bio |
Scott Thomas Latest Insider Activity
Tracking and analyzing the buying and selling activities of Scott Thomas against Seer stock is an integral part of due diligence when investing in Seer. Scott Thomas insider activity provides valuable insight into whether Seer is net buyers or sellers over its current business cycle. Note, Seer insiders must abide by specific rules, including filing SEC forms every time they buy or sell Seer'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Scott Thomas over a year ago Acquisition by Scott Thomas of 70000 shares of SeerInc subject to Rule 16b-3 |
Seer Management Efficiency
The company has return on total asset (ROA) of (0.1492) % which means that it has lost $0.1492 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2203) %, meaning that it created substantial loss on money invested by shareholders. Seer's management efficiency ratios could be used to measure how well Seer manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/27/2024, Return On Tangible Assets is likely to drop to -0.21. In addition to that, Return On Capital Employed is likely to drop to -0.26. At this time, Seer's Fixed Asset Turnover is relatively stable compared to the past year. As of 11/27/2024, Asset Turnover is likely to grow to 0.04, while Total Assets are likely to drop slightly above 372.6 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Josh Eizen | AN2 Therapeutics | N/A | |
| Maryann Cimino | Pharvaris BV | N/A | |
| Jeffrey Trigilio | Cullinan Oncology LLC | 40 | |
| Rita Kwong | Nurix Therapeutics | N/A | |
| MS MD | Oric Pharmaceuticals | 57 | |
| Ajim CFA | Monte Rosa Therapeutics | 47 | |
| John Kuriyan | Nurix Therapeutics | N/A | |
| DPhil DPHIL | Kymera Therapeutics | 48 | |
| Lori Friedman | Oric Pharmaceuticals | 60 | |
| Morgan Conn | Pharvaris BV | 55 | |
| Michael McKenna | QuantumSi | 62 | |
| John Castle | Monte Rosa Therapeutics | 53 | |
| Yuichi MD | MediciNova | 74 | |
| Matthew Stanton | Generation Bio Co | 51 | |
| Kyle Breidenstine | PepGen | N/A | |
| Rex CFA | Anebulo Pharmaceuticals | 64 | |
| Annick Deschoolmeester | Pharvaris BV | 51 | |
| Crystal MD | Lyell Immunopharma | 63 | |
| MBA MD | Generation Bio Co | 55 | |
| Silvia Buonamici | Monte Rosa Therapeutics | N/A | |
| Joseph Zakrzewski | AN2 Therapeutics | 62 | |
Management Performance
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.15 |
Seer Inc Leadership Team
Elected by the shareholders, the Seer's board of directors comprises two types of representatives: Seer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Seer. The board's role is to monitor Seer's management team and ensure that shareholders' interests are well served. Seer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Seer's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marissa Dixon, Chief Officer | ||
| Asim Siddiqui, Senior Development | ||
| Martin Goldberg, Senior Development | ||
| Kenny Ross, Chief Officer | ||
| JD Esq, Chief Secretary | ||
| Joe Laws, Chief CoFounder | ||
| David Horn, President,Treasurer CFO | ||
| Serafim Batzoglou, Chief Officer | ||
| Scott Thomas, Chief Officer | ||
| Karen Possemato, Chief Officer | ||
| Christopher Mason, Member Board |
Seer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Seer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.15 | ||||
| Operating Margin | (6.03) % | ||||
| Current Valuation | (80.76 M) | ||||
| Shares Outstanding | 54.92 M | ||||
| Shares Owned By Insiders | 4.97 % | ||||
| Shares Owned By Institutions | 63.82 % | ||||
| Number Of Shares Shorted | 978.84 K | ||||
| Price To Book | 0.41 X | ||||
| Price To Sales | 9.61 X |
Pair Trading with Seer
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Seer position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Seer will appreciate offsetting losses from the drop in the long position's value.Moving against Seer Stock
| 0.89 | VALN | Valneva SE ADR | PairCorr |
| 0.8 | ERNA | Eterna Therapeutics | PairCorr |
| 0.77 | ME | 23Andme Holding | PairCorr |
| 0.74 | HLN | Haleon plc | PairCorr |
| 0.59 | VCNX | Vaccinex | PairCorr |
The ability to find closely correlated positions to Seer could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Seer when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Seer - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Seer Inc to buy it.
The correlation of Seer is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Seer moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Seer Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Seer can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Seer Stock Analysis
When running Seer's price analysis, check to measure Seer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Seer is operating at the current time. Most of Seer's value examination focuses on studying past and present price action to predict the probability of Seer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Seer's price. Additionally, you may evaluate how the addition of Seer to your portfolios can decrease your overall portfolio volatility.